OCS Stock Analysis: Buy, Sell, or Hold?
OCS - Oculis Holding AG Ordinary shares
$28.45
0.21 (0.76%)
▲
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 10, 2026
Get Alerted When OCS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: OCS is 7.3% above fair value ($26.52). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: OCS is 7.3% above fair value ($26.52). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: OCS is currently trading at $28.45, which is considered extended relative to its 30-day fair value range of $20.35 to $26.52.
Technical Outlook: Technically, OCS is in a uptrend. The price is approaching resistance at $28.99. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: OCS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $46.29 (+64.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, OCS is in a uptrend. The price is approaching resistance at $28.99. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: OCS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $46.29 (+64.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$20.35 -
$26.52
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
Protect Your Profits
OCS is technically overbought (RSI 84). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+7.3% above fair value)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 64.0% below Wall St target ($46.29)
Fair Price Analysis
30-Day Fair Range
$20.35 -
$26.52
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$23.61
Resistance Level
$28.99
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-15.48
Wall Street Target
$46.29
(+64.0%)
Revenue Growth (YoY)
12.5%
Last updated: January 30, 2026 5:39 PM ET
Data refreshes hourly during market hours. Next update: 6:39 PM
Data refreshes hourly during market hours. Next update: 6:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OCS showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$85 | 55 HOLD |
Advanced OCS Option Strategies
Professional options setups generated by AI based on today's OCS price and gamma walls.
